Should Centralized Histopathological Review in Prostate Cancer be the Gold Standard?

To assess the potential impact of centralized histopathological review on prostate cancer management. Methods: Biopsy slides of 277 men with newly diagnosed prostate cancer between January 2010 and March 2014 from 22 centers were referred to our tertiary referral center for centralized histopathological review.

The biopsy Gleason score and D’Amico prognostic risk group were compared between those of the referring pathologists and those after assessment by a centralized histopathological review committee consisting of two specialized uro-pathologists.

Alterations in biopsy Gleason score and D’Amico prognostic risk group between referring pathologists and centralized histopathological committee were subdivided into treatment changes (i.e., lymph-node dissection, nerve sparing surgery, or active surveillance) and diagnostic changes (bone scintigraphy).

PDF LINK